“Datroway: AstraZeneca’s FDA-Approved Lung Cancer Treatment”
AstraZeneca and Daiichi Sankyo secure FDA approval for Datroway, achieving a crucial milestone in cancer treatment. Approved for advanced non-small cell lung cancer, Datroway is the first U.S. drug to go beyond breast cancer, offering hope to patients with TROP2-expressing tumors, and expanding the arsenal in the ongoing fight against cancer. Read more
Read More
“FactSet Q3 Earnings Miss Amid Strong Revenue Growth, Stable Outlook”
"Q3 fiscal results for FactSet Research Systems exceeded revenue expectations, demonstrating resilience in a challenging financial industry. Its wealth management and institutional buy-side segments performed particularly strongly, contributing to overall business growth. The company's management remains optimistic about future prospects, reinforcing FactSet's potential for sustained growth." Read more
Read More
“BofA Raises e.l.f. Beauty’s Price Target Amid Margin Pressure”
BofA Securities ups e.l.f. Beauty's price target from $113 to $135 while maintaining a 'Buy' rating, showing confidence in its long-term potential despite weaker Q1 projections. The revised price target reflects the beauty company's resilience amidst tariff impacts and its focus on cost efficiency. Read more
Read More